A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas
NCT00526812
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
54
Enrollment
INDUSTRY
Sponsor class
Conditions
Glioma
Interventions
DRUG:
RTA 744
DRUG:
RTA 744 injection
Sponsor
Biogen